Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion

Everolimus-eluting Bioresorbable Vascular Scaffolds Versus Everolimus-eluting Stents in Patients With Chronic Total Occlusion

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02739685

Acronym

SCORE-CTO

Enrollment

Registered

2016-04-15

Start date

2016-09-30

Completion date

2017-01-31

Last updated

2019-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The purpose of the current study is to demonstrate non-inferiority of everolimus-eluting bioresorbable vascular scaffold to everolimus-eluting stents in patients with chronic total occlusion regarding the antirestenotic efficacy at 8 to 10-month angiographic follow-up.

Interventions

DEVICEEverolimus-eluting bioresorbable vascular scaffold

Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion

DEVICEEverolimus-eluting stent

Implantation of everolimus-eluting stent in chronic total occlusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Clinical inclusion criteria: * Age ≥18 years * Angina pectoris, equivalent symptoms, and/or positive stress test * Viable myocardium subtended by chronic total occlusion * Negative pregnancy test in women with childbearing potential Angiographic inclusion criteria: * Chronic total occlusion defined as Thrombolysis in Myocardial Infarction flow 0 with an estimated duration ≥3 months * Successful wire passage and assumption of successful stent/scaffold deployment * Target reference vessel diameter 2.5 - 4.0 mm

Exclusion criteria

Clinical

Design outcomes

Primary

Measure	Time frame
In-stent late lumen loss assessed by angiography	8-10 months after the index procedure

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026